tirzepatide approved in canada Dual Agonist (GLP-1/GIP) FDA approves new version of

Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice

No Instructions Provided We do not provide dosage recommendations, administration instructions, or reconstitution guidance

Avoid the same spot for at least four weeks to prevent lipodystrophy and maintain consistent absorption

When both pathways are activated together, the weight loss effects appear to be additive or even synergistic, which is why tirzepatide has demonstrated superior weight loss outcomes compared to semaglutide alone in head-to-head comparisons

Women and hormonal considerations Both medications affect hormonal balance through weight loss

Working with a skilled clinician can help you decide which weight loss drug is right for you and what lifestyle changes you should focus on to support it